Welcome to August! Let's take a look back at July:
We'd like to welcome Regeneron as a new NICA Corporate Partner!
We began a great working relationship with Regeneron earlier this year when partnering to provide COVID-19 guidance and resources, and we are honored to continue to work with them in this new capacity.

Does your organization directly manufacture IV or injectable medications? Click the button on the right to email us and learn about becoming a NICA Corporate Partner.
Have you seen the #NICA2021 testimonials?
We are so glad that our virtual platform exceeded attendees’ expectations and that everyone was able to take loads of key info and inspiration away from the meeting to continue to provide the most efficient, safe, and high-quality care settings for some of the nation’s most vulnerable patients.
Save the date for #NICA2022!
Already excited for next year's Annual Meeting? Mark your calendars for what promises to be an unforgettable return to in-person meetings. We’ll see you June 17-18, 2022 at the Hyatt Regency New Orleans in New Orleans, Louisiana!
This past month, we updated our Advocacy Toolkit to help equip providers to take action against harmful practices that would threaten the non-hospital, community-based delivery channel for provider-administered medications.
Has your practice been affected by specialty pharmacy mandates?
Within our toolkit, you can download and customize letters to let decision-makers know how your practice would be negatively impacted by specialty pharmacy mandates.
NICA shares our concerns with Cigna's "Shared Savings Program"

We received concerned reports from providers regarding Cigna's "Shared Savings Program", a policy that offers $500 debit cards to patients who switch from Remicade to a preferred alternative, either Avsola or Inflectra.

NICA has always held that non-medical switching is a dangerous practice that devalues provider expertise, and with the addition of that financial compensation, we are deeply concerned with how this policy will affect patient health.
Has your practice recently been impacted by payor delays in high-dollar claims?
NICA has also heard from several of our provider member offices that they are experiencing major delays in high-dollar reimbursement claims for drugs like Ocrevus and Tysabri. If this has happened for your practice, please let us know, so that we can help you get paid.

Email us at advocacy@infusioncenter.org or by clicking the button below and be sure to include the payor involved, the drug involved, and any documentation that would be relevant in compiling a case against the offending payors.
Thank you for being an engaged supporter of NICA and for taking the time to inform our advocacy efforts. Stay up to date with us by following us on social media! We hope you are enjoying your summer and staying safe and healthy.
‌
‌
Brian Nyquist, MPH
President & CEO, National Infusion Center Association
Want more NICA news and updates on resources? 👇
Follow National Infusion Center Association on social media